Introduction: Autonomic dysfunction is common in chronic obstructive pulmonary disease (COPD), and worse autonomic function may be a marker of risk for acute exacerbations of COPD (AECOPD). Heart rate variability (HRV) is a measure of autonomic function. Our objective was to test whether lower (worse) HRV is a risk factor for AECOPD.
Methods: We measured standard deviation of normal RR intervals (SDNN) and root mean square of successive RR interval differences (RMSSD) on 10-second electrocardiograms (ECGs) performed at screening and day 42 in participants in the Beta Blockers for the Prevention of Acute Exacerbations of COPD trial ( BLOCK-COPD), a placebo-controlled trial of metoprolol for prevention of AECOPD. We used Cox-proportional hazards models to test if these HRV measures were associated with risk of any AECOPD, and separately, hospitalized AECOPD. We tested associations using baseline HRV measures and incorporating HRV measures from day 42 as a time-varying covariate. We also tested for interactions with metoprolol assignment.
Results: Of 532 trial participants, 529 (forced expiratory volume in 1 second [FEV 1 ]41 ± 16.3 % predicted) were included in this analysis. We did not find a significant association between HRV measures and risk of AECOPD when all participants were analyzed together. There was a significant interaction between RMSSD and assignment to metoprolol on time to first hospitalized AECOPD; in the placebo group greater RMSSD was associated with a lower risk of hospitalized AECOPD (adjusted hazard ratio0.71, 95% confidence interval: 0.52 to 0.96, per 10 ms increase) but there was no association in the metoprolol group.
Conclusions: Autonomic dysfunction as measured by HRV may be a risk factor for AECOPD. Future studies should analyze longer HRV recordings and their performance in broader samples of people with COPD, including those on beta-blockers.
Bibliographical noteFunding Information:
Abbreviations: chronic obstructive pulmonary disease, COPD; acute exacerbation of COPD, AECOPD; heart rate variability, HRV; standard deviation of normal RR intervals, SDNN; root mean square of successive RR interval differences, RMSSD; electrocardiograms, ECGs; Beta Blockers for the Prevention of Acute Exacerbations of COPD trial, BLOCK COPD; forced expiratory volume in 1 second,FEV1; confidence interval, CI; forced vital capacity, FVC; long-acting muscarinic antagonists, LAMAs; St George’s Respiratory Questionnaire, SGRQ; locally estimated scatterplot smoothing line, LOESS; standard deviation, SD; interquartile range, IQR; adjusted hazard ratio, aHR Funding Support: The Beta-Blockers for the Prevention of Acute Exacerbations of COPD trial (BLOCK COPD) was supported by a grant from the Department of Defense (W81XWH-15-1-0705). DMM was supported by the University of Minnesota T32 Training in Lung Science training grant (2T32HL007741-26A1). This material is also the result of work supported with resources and the use of facilities at the Minneapolis VA Medical Center, Minneapolis. The views expressed in this article are those of the authors and do not reflect the views of the United States Government, the Department of Defense, the Department of Veterans Affairs, or any of the authors’ affiliated academic institutions.
SA has received research grants from Medtronic. RC has received grant support, advisory board fees, or lecture fees from GlaxoSmithKline, Boehringer Ingelheim, and AstraZeneca, consulting fees from Regeneron and Genentech, and reports owning stock in Inogen. HBR is supported by grants from National Institutes of Health (R01HL151452, R01HL153460, P50HD098593, R01DK122767, P2CHD086851), the Tobacco-Related Disease Research Program (T31IP1666), and the University of California, Office of the President. He reports consulting fees from Omniox Inc., and is involved in contracted clinical research with Boehringer Ingelheim, GlaxoSmithKline, Novartis, AstraZeneca, Astellas, United Therapeutics, Genentech and Regeneron. He is a visiting Professor at the University of Leeds, United Kingdom. WWS has received grant support from AstraZeneca and Boehringer Ingelheim, consulting fees and fees for serving on a data and safety monitoring board from Allergan, and fees for serving on a data and safety monitoring board from Syneos Health. MTD has received grant support from the National Institutes of Health, the Department of Defense, and the American Lung Association; consulting from AstraZeneca, GlaxoSmithKline, Pulmonx, and Teva; and contracted clinical trial support from Boehringer Ingelheim, Boston Scientific, Gala, Nuvaira, and Pulmonx. KMK has received consulting fees from Nuvaria and Allergan. The remaining authors have nothing to declare.
© 2022 COPD Foundation. All rights reserved.
- acute exacerbation of COPD
- autonomic nervous system
- heart rate variability
PubMed: MeSH publication types
- Journal Article